633 related articles for article (PubMed ID: 31358513)
1. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
[TBL] [Abstract][Full Text] [Related]
3. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
[TBL] [Abstract][Full Text] [Related]
4. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
6. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
[TBL] [Abstract][Full Text] [Related]
7. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
[TBL] [Abstract][Full Text] [Related]
8. Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors.
Menezes B; Linderman JJ; Thurber GM
Drug Metab Dispos; 2022 Jan; 50(1):8-16. PubMed ID: 34649966
[TBL] [Abstract][Full Text] [Related]
9. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
[TBL] [Abstract][Full Text] [Related]
11. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
[TBL] [Abstract][Full Text] [Related]
15. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
18. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
Shah DK; Haddish-Berhane N; Betts A
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
[TBL] [Abstract][Full Text] [Related]
19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
20. Anti-Lymphocyte Antigen 6 Complex, Locus E-
Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
